Peter Gilbert and SCHARP researchers, HVTN Laboratory Program, part of worldwide effort to understand trial outcome, influence future HIV vaccine studies
April 9, 2012
Fred Hutchinson Cancer Research Center researchers played a key role in the discovery of important immune responses that may have protected some volunteers from HIV in the RV144 Thai trial, the first HIV vaccine trial to show modest effectiveness in preventing HIV infection. Results from extensive RV144 laboratory studies were published April 5 in the New England Journal of Medicine.
Overbaugh, Cortez-led study shows women infected by two different HIV strains exhibit strong antibody response; findings may aid vaccine development
April 2, 2012
| By Kristen Woodward
Researchers at the Fred Hutchinson Cancer Research Center found that women who have been infected by two different strains of HIV from two different sexual partners-a condition known as HIV superinfection-have more potent antibody responses that block the replication of the virus compared to women who've only been infected once.
The Fred Hutchinson Cancer Research Center’s Dr. Catherine Blish is the recipient of an Interscience Conference on Antimicrobial Agents and Chemotherapy Young Investigator Award from the American Society for Microbiology for her work elucidating the role of neutralizing antibodies in HIV transmission.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.